Immunosuppressive therapy.
Although Cyclosporin A has improved transplant outcome, its use has serious limitations due to its narrow therapeutic window. New approaches to broaden this window exploit alternative drug formulations, pharmacokinetic profiling and new immunosuppressive agents, such as Rapamycin and Brequinar, which act in a synergistic fashion. There is no evidence to suggest that the pharmacological alternative to Cyclosporin A, FK-506, displays a broader therapeutic window, although it may be tenfold more potent. Similarly, despite the specificity of the IgG2a mouse anti-human CD3 monoclonal antibody, it displays a significant range of clinical side effects, delayed therapeutic action and frequently stimulates generation of human anti-mouse monoclonal antibodies. Recent advances in monoclonal antibody technology seek not only to produce antibodies against determinants involved in alloactivation, but also to 'humanize' the antibodies for reduced side effects. The availability of this array of potential agents highlights the need to develop guidelines for clinical trial methodologies to address the unique needs and demands of organ transplantation.
Kahan
B D
BD
Department of Surgery, University of Texas Health Science Center, Houston 77030.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D017472:Receptors, Interleukin-1 / Q000187:drug effects; D019948:Receptors, Interleukin-4; D011975:Receptors, Mitogen / Q000187:drug effects
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D017472:Receptors, Interleukin-1; D019948:Receptors, Interleukin-4; D011975:Receptors, Mitogen